Vancouver-based Absci valued at nearly $2 billion in IPO trading
Published: July 22, 2021, 6:28pm
Share:
Sean McClain, founder and CEO of AbSci in downtown Vancouver. (Amanda Cowan/The Columbian files)
Vancouver-based biotechnology firm Absci held an initial public offering Thursday, resulting in a valuation of nearly $2 billion. The news comes a little more than a year after the company first filed a registration statement declaring its IPO plans.
Absci’s stock trades on the Nasdaq under the symbol ABSI. The company announced Wednesday that it would offer 12.5 million shares of common stock at $16 per share, with the goal of netting $200 million in gross proceeds.